Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02943785 · ClinicalTrials.gov registry record · Phase 3
Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,426
- Enrollment target
NCT02943785 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 1,426 participants.
The verdict
NCT02943785, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,426 participants
- Enrollment target
Study Summary
When the upper chambers of a person's heart receive or generate irregular electrical signals, it causes abnormal rhythm in the heartbeat. This is called atrial fibrillation. Atrial fibrillation goes along with blood clots that may cause mainly strokes and less often other diseases, such as a heart attack. Some patients with atrial fibrillation have other heart disease, such as heart valves that may need to be replaced using catheters. Often doctors give patients drugs that reduce those blood clots. These are either vitamin K antagonist (VKA) or direct anticoagulants, such as edoxaban. In these patients, it is unclear which of the drugs is better for reducing stroke without increasing severe bleedings.
Interventions
- DRUG Edoxaban-based Regimen
- DRUG VKA-based Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,426 participants |
| Start Date | 2017-03-21 |
| Est. Completion | 2021-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02943785
The ClinicalTrials.gov registry entry for NCT02943785 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Edoxaban-based Regimen is the first listed.
NCT02943785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02943785 about?
NCT02943785 is a clinical study titled "Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)". When the upper chambers of a person's heart receive or generate irregular electrical signals, it causes abnormal rhythm in the heartbeat. This is called atrial fibrillation. Atrial fibrillation goes along with blood clots that may cause mainly strokes and less often other diseases, such as a heart ...
What is the current status of trial NCT02943785?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,426 participants. The study started on 2017-03-21. Estimated completion is 2021-02-28.
What interventions are being tested in trial NCT02943785?
The interventions under investigation include: Edoxaban-based Regimen (DRUG), VKA-based Regimen (DRUG).
Who is sponsoring clinical trial NCT02943785?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.